PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00054665 |
|
Recruitment Status :
Completed
First Posted : February 6, 2003
Results First Posted : September 11, 2012
Last Update Posted : September 11, 2012
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
This study will examine the safety and effectiveness of an experimental drug called Bortezomib (PS-341), given alone and in combination with a chemotherapy regimen called Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and Filgrastim (EPOCH), in treating non-Hodgkin's B-cell lymphoma. In the laboratory, PS-341 kills lymphoma cells and makes them more sensitive to chemotherapy. The EPOCH treatment regimen includes the drugs doxorubicin, etoposide, vincristine, cyclophosphamide, prednisone, and filgrastim.
Patients 18 years of age and older with an aggressive non-Hodgkin's lymphoma that has relapsed after treatment or is not responding to chemotherapy may be eligible for this study. Candidates will be screened with a medical history and physical examination. Other tests that may be required include blood and urine tests; lung function studies; imaging tests such as magnetic resonance imaging, computed tomography and x-rays; and biopsy (surgical removal of a small tissue sample) of tumor, bone marrow, or other tissue.
Upon entering the study, all participants will receive PS-341. The drug is given as a 3- to 5-second intravenous (through a vein) injection twice a week for 2 weeks. This is followed by a 1-week rest. Each 3-week period comprises one treatment cycle. The number of cycles a patient receives depends on how well he or she responds to the drug. Patients who do not have a complete remission or whose tumor grows on this therapy will be offered PS-341 in combination with up to six cycles of EPOCH chemotherapy. The treatment for patients taking PS-341 plus EPOCH is as follows:
- PS-341, given by 3- to 5-second intravenous (IV) injection on days 1 and 4 of each cycle.
- Doxorubicin, etoposide, and vincristine, given by continuous IV infusion over 4 days, beginning on day 1 and ending on day 5 of each cycle. The drugs are delivered through a lightweight portable infusion pump to an indwelling IV catheter (plastic tube) in a vein.
- Cyclophosphamide, given by IV infusion over 15 minutes on day 5 of each cycle.
- Prednisone, given by mouth (pills) twice a day on days 1 through 5 of each cycle.
- Filgrastim, given by injection under the skin starting on day 6 of each cycle and continuing until the white blood cell count increases or until day 19 of the cycle.
Patients also take a combination of antibiotics 3 days a week during EPOCH to prevent infection while resistance is lowered because of the chemotherapy. Etoposide, doxorubicin, and cyclophosphamide doses are adjusted as needed, based on white blood cell counts of the previous cycle. The first patients in the study will receive a low dose of PS-341. The dose will be increased in subsequent small groups of patients as long as the preceding dose is well tolerated.
Drug therapy for patients who are candidates for bone marrow transplant will be tailored to permit transplantation. Patients who are not eligible for or who choose not to have a bone marrow transplant will be followed at the National Institutes of Health (NIH) every 3 months the first year, every 4 months the second year, every 6 months the third year, and then once a year until their disease progresses or the study ends. Patients may have tumor and bone marrow biopsies, blood draws, and computed tomography (CT) scans periodically to evaluate disease status and drug side effects.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| B-Cell Lymphoma | Drug: PS-341 Drug: Etoposide Drug: Doxorubicin Drug: Vincristine Drug: Cyclophosphamide Drug: Prednisone Drug: Filgrastim | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 50 participants |
| Allocation: | Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | PS-341 and PS-341 + Epoch Chemotherapy and Molecular Profiling in Relapsed or Refractory Diffuse Large B-Cell Lymphomas |
| Study Start Date : | February 2003 |
| Actual Primary Completion Date : | September 2008 |
| Actual Study Completion Date : | July 2009 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Part A: PS-341 Alone
1.3 mg/m^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
|
Drug: PS-341
1.3 mg/m^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
Other Names:
|
|
Experimental: Part B: PS-341 & EPOCH
PS-341: level 1: 0.5 mg/m^2 intravenous (IV) days 1, 4; level 2: 1.0 mg/m^2 IV days 1, 4; level 3: 1.5 mg/m^2 IV days 1, 4; level 4: 1.7 mg/m^2 IV days 1, 4. EPOCH: Etoposide: 50 mg/m^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion; Doxorubicin: 10 mg/m^2 day CIV days 1-4, 96 hour infusion; Vincristine: 0.4 mg/m^2 day CIV days 1-4, 96 hour infusion; Cyclophosphamide: 750 mg/m^2 day IV day 5 bolus; Prednisone: 60 mg/m^2 by mouth twice a day days 1-5; Filgrastim: 300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm^3. Repeat cycles every 21 days. |
Drug: PS-341
1.3 mg/m^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
Other Names:
Drug: Etoposide 50 mg/m^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion. Repeat cycle every 21 days.
Other Names:
Drug: Doxorubicin 10 mg/m^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
Other Name: Adriamycin Drug: Vincristine 0.4 mg/m^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
Other Name: Oncovin Drug: Cyclophosphamide 750 mg/m^2 day IV day 5 bolus. Repeat cycle every 21 days.
Other Name: Cytoxan Drug: Prednisone 60 mg/m^2 by mouth twice a day days 1-5. Repeat cycle every 21 days.
Other Name: Deltasone Drug: Filgrastim 300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm^3. Repeat cycle every 21 days.
Other Name: Neupogen |
- Clinical Response Rate [ Time Frame: 18 weeks ]Clinical Response Rate is the number of participants with a partial and complete response assessed by the criteria for lymphoma. A complete response is complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy and normalization of those biochemical abnormalities. Partial response is a greater than or equal to 50% decrease in the sum of the products of the greatest diameters of 6 largest dominant nodes or nodal masses. No increase in size of nodes, liver or spleen and no new sites of disease
- Number of Participants With Adverse Events [ Time Frame: 43 months ]Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
- ELIGIBILITY CRITERIA:
Large B-cell lymphoma (subtypes: DLBCL (diffuse large B-cell lymphoma);
mediastinal (thymic) large B-cell lymphoma;
transformed large B-cell lymphoma;
follicular grade IIIB large B-cell lymphoma;
intravascular large B-cell lymphoma).
Confirmed pathological diagnosis at the treating institution.
Prior anthracycline-based treatment.
Age greater than or equal to 18 years.
Available tumor tissue for biopsy.
Eastern Cooperative Oncology Group (ECOG) performance 2 or better.
Major organ function: Absolute neutrophil count (ANC) greater than or equal to 1,000/microliters,
Platelet greater than or equal to 50,000/microliters,
creatinine less than or equal to 1.5 mg/dl or creatinine clearance greater than 60 cc/min;
serum glutamic pyruvic transaminase (SGPT) less than 5 x upper limit of normal;
bilirubin less than 2 mg/dl (total) except less than 5 mg/dl in patients with Gilbert's syndrome as defined by greater than 80 percent unconjugated; unless impairment due to organ involvement by lymphoma.
Informed consent and willingness to use contraception by both men and women.
Not pregnant or nursing because of an unknown potential for teratogenic or abortifacient effects.
Both male and female patients must be willing to use adequate contraception.
Human immunodeficiency virus (HIV) serology negative.
HIV positive patients receiving combination anti-retroviral therapy are excluded from the study because of positive pharmacokinetic interactions with PS-341 or the combination of PS-341 and EPOCH.
Additionally, the biology of HIV associated DLBCL's is often quite different from HIV negative disease due to involvement of Epstein Barr Virus (EBV).
Hepatitis B surface antigen negative.
No symptomatic cardiac disease or cardiac ejection fraction less than 40 percent (in patients receiving EPOCH).
No active central nervous system (CNS) lymphoma.
No systemic cytotoxic or experimental treatments within 4 weeks of treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00054665
| United States, Maryland | |
| National Cancer Institute (NCI) | |
| Bethesda, Maryland, United States, 20892 | |
| United States, New York | |
| Roswell Parck Cancer Institute | |
| Buffalo, New York, United States, 14263 | |
| Principal Investigator: | Wyndham Wilson, M.D. | National Cancer Institute, National Institutes of Health |
Publications:
| Responsible Party: | Wyndham Wilson, Dr. Wyndham Wilson, National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00054665 |
| Obsolete Identifiers: | NCT00057902 |
| Other Study ID Numbers: |
030096 03-C-0096 |
| First Posted: | February 6, 2003 Key Record Dates |
| Results First Posted: | September 11, 2012 |
| Last Update Posted: | September 11, 2012 |
| Last Verified: | August 2012 |
|
BCL-2 NFK-B Drug Resistance |
Translational Lymphoma Large B-Cell Lymphoma |
|
Lymphoma Lymphoma, B-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Prednisone Cyclophosphamide Doxorubicin Etoposide Vincristine Bortezomib |
Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antibiotics, Antineoplastic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Anti-Inflammatory Agents Glucocorticoids |